MCRB / Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Kevin Mannix - Head, IR Eric more_horizontal

Seres Therapeutics trades near its 52-week low and presents an asymmetric risk-reward profile. The company's lead asset, SER-109, has successfully con more_horizontal

Seres Therapeutics (MCRB) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.61 more_horizontal

Biotech investing is a wild ride but share prices falling after FDA approval, as has just happened to Seres Therapeutics VOWST product, is pretty weir more_horizontal

Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might no more_horizontal

Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimat more_horizontal

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Carlo Tanzi - IR Officer Eric S more_horizontal

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the nu more_horizontal